MarketPulse

respiratory syncytial virus

2 articles
BenzingaBenzinga··Vandana Singh

GSK Expands RSV Vaccine Access to Younger High-Risk Adults, Broadening Market Opportunity

GSK's Arexvy RSV vaccine gains FDA approval for younger high-risk adults aged 18-49, expanding market beyond 60+ population on strong Phase 3b data and £198M Q4 sales.
GSKFDA approvalRSV vaccine
BenzingaBenzinga··Vandana Singh

Merck Seeks to Expand RSV Antibody Approval Following Positive Phase 3 Trial Results

Merck's RSV antibody Enflonsia shows positive Phase 3 results, supporting FDA expansion plans to protect more at-risk infants from respiratory syncytial virus infection.
MRKGSKmonoclonal antibodyFDA approval